コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ng a 12-dose regimen of weekly isoniazid and rifapentine.
2 hieve highly active once-weekly therapy with rifapentine.
3 wed increased susceptibility to rifampin and rifapentine.
6 ve pulmonary tuberculosis were randomized to rifapentine 10 mg/kg/dose or rifampin 10 mg/kg/dose, adm
8 ositive pulmonary tuberculosis were assigned rifapentine 10, 15, or 20 mg/kg or rifampin 10 mg/kg dai
9 were similar across groups (rifampin, 8.2%; rifapentine 10, 15, or 20 mg/kg, 3.4, 2.5, and 7.4%, res
10 continuation phase regimen of isoniazid plus rifapentine (10 mg/kg) is inferior to standard twice-wee
12 ng activity of once-weekly moxifloxacin plus rifapentine (15 mg/kg) was significantly greater than th
13 I with 3 months of once-weekly isoniazid and rifapentine (3HP) administered under directly observed t
14 kly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of ison
17 (6%), 2 of 51 (4%), and 3 of 47 (6%) in the rifapentine 600-, 900-, and 1,200-mg treatment arms, res
19 f directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combinatio
20 not taking antiretroviral therapy to receive rifapentine (900 mg) plus isoniazid (900 mg) weekly for
22 onths followed by moxifloxacin and 900 mg of rifapentine administered twice weekly for 2 months; or a
23 Three months of a once-weekly combination of rifapentine and isoniazid for treatment of latent tuberc
24 died the interaction of efavirenz with daily rifapentine and isoniazid in human immunodeficiency viru
28 included weekly administration of high-dose rifapentine and moxifloxacin was as effective as the con
29 e evaluated new treatment regimens including rifapentine and moxifloxacin, and assessed the potential
30 and protein-bound) plasma concentrations of rifapentine and of desacetyl rifapentine detected for mo
31 ression analyses, AUC(0-infinity) values for rifapentine and the active 25-desacetyl metabolite were
32 t the binding sites for rifampin, rifabutin, rifapentine, and sorangicin A are shared, whereas the bi
33 ing two rifamycin derivatives, rifabutin and rifapentine, and streptolydigin and sorangicin A, which
34 er among rifapentine recipients who had high rifapentine areas under the concentration-time curve.
36 ility, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body wei
37 ospective, randomized, double-blind trial of rifapentine at three doses (600, 900, and 1,200 mg) plus
38 nfinity)) increased significantly with dose (rifapentine AUC(0- infinity): 296, 410, and 477 microg.h
40 sterilizing activity of improved once-weekly rifapentine-based continuation phase regimens in a murin
41 ticipants received once-weekly isoniazid and rifapentine by direct observation, self-administration w
42 tion and safety of once-weekly isoniazid and rifapentine by self-administration versus direct observa
44 e efficacy of the once-weekly isoniazid plus rifapentine continuation phase regimen can be increased
46 for isoniazid and an increase in the dose of rifapentine could augment the activity of once-weekly re
47 ncentrations of rifapentine and of desacetyl rifapentine detected for more than 36 hours after cleara
51 nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time
54 d to determine if regimens that deliver high rifapentine exposures can shorten treatment duration to
60 rifampin group and 133 of 196 (67.9%) in the rifapentine group (difference, 2.8%; 95% CI: -6.9, 12.4)
61 p and 171 of 198 participants (86.4%) in the rifapentine group (difference, 3.0%; 95% confidence inte
62 f five relapses in the once-weekly isoniazid/rifapentine group had monoresistance to rifamycin, compa
63 up and 40 of 275 participants (14.5%) in the rifapentine group prematurely discontinued treatment (P=
64 of 30 patients in the once-weekly isoniazid/rifapentine group relapsed, compared with three of 31 pa
66 hort-course directly observed isoniazid plus rifapentine (INH/RPT) combination could have potential a
68 r death were 3.1 per 100 person-years in the rifapentine-isoniazid group, 2.9 per 100 person-years in
70 niazid (INH), 4-month rifampin (RIF), weekly rifapentine/isoniazid (RPT/INH) for 12 weeks, or no trea
71 d 9.8 L/hour (IQR, 7.04-15.59 L/hour) during rifapentine/isoniazid treatment (GMR, 1.04 [90% confiden
72 or 3 months of directly observed once-weekly rifapentine (maximum dose, 900 mg) plus isoniazid (maxim
73 h failure/relapse with once-weekly isoniazid/rifapentine (median isoniazid area under the concentrati
75 andomly assigned 900 mg isoniazid and 600 mg rifapentine once weekly, or 900 mg isoniazid and 600 mg
76 Neither a 3-month course of intermittent rifapentine or rifampin with isoniazid nor continuous is
77 ated with outcome with once-weekly isoniazid/rifapentine (p = 0.03) but not twice-weekly isoniazid/ri
81 n = 6886) found that 3 months of once-weekly rifapentine plus isoniazid was noninferior to 9 months o
82 the end of intensive phase was higher among rifapentine recipients who had high rifapentine areas un
86 hange of CT was higher in subjects receiving rifapentine than in subjects receiving standard-dose rif
88 for isoniazid and by increasing the dose of rifapentine to a clinically acceptable level of 15 mg/kg
89 self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis infection in th
90 red the antimicrobial activity and safety of rifapentine vs rifampin during the first 8 weeks of pulm
94 pared a once-weekly regimen of isoniazid and rifapentine with twice weekly isoniazid and rifampin in
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。